Orvosi Hetilap, 2004. november (145. évfolyam, 45-48. szám)

2004-11-21 / 47. szám - Halmos Tamás: A diabetes mellitus kezelésének aktuális kérdései

diabetes. Diabetes Care, 2004, 27 (Suppl. 1), S68-S7. - 4. Barzilay, J., Freedland, E.: Inflammation and it's association with glucose disorders and vascular diseases. Treatment in Endocrinology, 2003. 2, 85-94. - 5. Bretzel, R. G., Arnolds, S„ Medding, J. és mtsai: A direct efficacy and safety comparison of insulin aspart, human so­luble insulin and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care, 2004, 27, 1023-1027. - 6. Bloom­­garden, Z. I: The 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care, 2004, 27, 602-609. - 7. Bloomgarden, Z. T: Aspects of blood pressure, lipid and glycemic treatment. Dia­betes Care, 2004, 27, 264-269. - 8. Buteau, J., El-Assad, W., Rhodes, C. J. és mtsai: Glucagon-like peptide-1 prevents beta-cell gluco-li­­potoxicity. Diabetologia, 2004, 47, 806-815. - 9. DCCT Research Group: The effect of intesive treatment of diabetes on the develop­ment and progression of long-term complications in insulin-de­­pendent diabetes mellitus. N. Engl. J. Med. 1993, 329, 977-986. - 10. Damci, T, Yalin, S„ Baki, H. és mtsai: Orlistat augments post­prandial increases in glucagon-like peptide-1 in obese type 2 dia­betic patients. Diabetes Care, 2004, 27, 1077-1080. - 11. Farmer, J. A., Torre, Amione, G.: Atherosclerosis and inflammation. Current Atherosclerosis Reports, 2002, 4, 92-98. - 12. Franz, M. J., Bantle, J. P., Beebe, C. A. és mtsai: Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Technical Review). Diabetes Care, 2002, 25, 148-198. - 13. Halmos T.: A diabetes szindróma új diag­nosztikai és klasszifikációs rendszere. Orv. Hetil. 2002, 143, 2523- 2532. - 14. Halmos T: Az elhízás epidémiája. Magyar Tudomány, 1999, 7, 838-847. - 15. Halmos T: A 2-es típusú cukorbetegség járványszerű megjelenése. Magyar Tudomány, 2000, 9, 300-315. -16. Halmos T, Jermendy, Gy.: Metabolikus x-szindróma az ezred­fordulón (elméleti vonatkozások és gyakorlati teendők). Orv. He­til. 2000, 141, 2701-2710. - 17. Haller, H.: Postprandial glucose and vascular disease. Diabetic Medicine, 1997, 14, S50-56. - 18. Hanefeld, M„ Bouter, K. P„ Dickinson, S. és mtsai: Rapid, and short-ac­ting meal time insulin secretion with nateglinid controls both prandial and mean glycemia. Diabetes Care, 2000, 23, 202-207. - 19. Hayden, M., Pignone, M„ Phillips, C.: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US. Preventive Services Task Force. Ann. Intern. Med., 2002, 136, 161-171. - 20. Hanefeld, M„ Brunetti, P., Schernthaner, G. H. és mtsai: One year glycemic control with a sulfonylurea plus pi­­oglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care, 2004, 27, 141-147. - 21. Herman­­sen, K„ Fontaine, P, Kukolja, K. K. és mtsai: Insulin analogues (insu­lin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004, 47, 622-619. - 21/a. Hermansen, K., Rönnemaa, T, Petersen, A. H. és mtsai: Inten­sive therapy with inhaled insulin via the AERx insulin diabetes management system. Diabetes Care, 2004, 27, 162-167. - 22. Ho­me, Pit., Bartley, P, Russel-Jones, D. és mtsai: Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes. Diabetes Care, 2004, 27, 1081-1087. - 23. Holst, J. J.: Therapy of type 2 diabetes mellitus based on the acti­ons of glucagon-like peptide-1. Diabetes Metab. Res. Rev., 2002, 18, 430-441. - 24. Jakab L.: Az atheroscleosis pathogenesise. Orv. Hetik, 2003, 124, 221-228. - 25. Jermendy Gy: Szív- és érrendsze­ri megbetegedések megelőzése diabetes mellhúsban. A primaer prevenció gyógyszerei. Diabetok Hung., 2003, XI, 233-246. - 26. Jermendy Gy.: Szív-és érrendszeri megbetegedések megelőzés dia­betes mellhúsban. A secundaer prevenció gyógyszerei. Diabetok Hung., 2004, XII, 5-20. - 27. Joslin, E. P: The treatment of diabe­tes mellitus in Treatment of diabetes mellitus. Lea and Fibiger, Szerk.: Joslin, E. P„ Root, H. F„ White P. és mtsa: Philadelphia, 1959, 243-300. old. - 28. Kautzky L., Halmos T„ Fövényi J. és mtsai: A glukóz variabilitás és a glycemia javulása inzulinpumpa (CSII) használatával. Tapasztalatok 37 beteg követése kapcsán. Diabetok Hung., 2004, Suppl. 1, XII, 69. - 29. Kelley, D„ Kuller, L. H„ McKo­­lanis, M. és mtsai: Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 di­abetes. Diabetes Care, 2004, 27, 33-40. - 29/a. Korytkowskí, M. T: Sulfonylurea treatment of type 2 diabetes mellitus: Focus on gli­­mepirid. Pharmacotherapy, 2004, 24,606-620. - 30. Lawrence, M., Reid, J., Taylor, G. J. és mtsai: Favorable effects of pioglitazon and metformin compared with gliclazide on lipoprotein subfractions in ovenweight patients with early type 2 diabetes. Diabetes Care, 2004, 27, 41-46. - 31. Lopez-Virella, M. F„ Mironova, M„ Stephan, E. és mtsai: Role of simvastatin as an immunomodulator in type 2 di­abetes. Diabetes Care, 2004, 27, 908-913. - 32. Mensitig, C„ Bou­cher, J., Cypress, M. és mtsai: National standards for diabetes self-ma­nagement education. Diabetes Care, 2004, 27, (Suppl. 1.), SMS­­ISO. - 32/a. Meyers G. M.: Az influenza elleni oltással megelőzhe­tő a szivinfarctus, a stroke és a hirtelen halál. Current Atherosc­lerosis Reports (magyar nyelvű kiadás), 2003, 4, 704-708. - 33. Nesto, R. W., Bell, D., Bonow, 0. R. és mtsai: Thiazolidinedione use, fluid retention, and congestive heart failure. Diabetes Care, 2004, 27, 256-263. - 34. Nolan, J. J., Ludvik, B„ Beerdsen, P. és mtsai: Im­provement in glucose tolerance and insulin resistance in obese subjects, treated with troglitazone. N. Engl. J. Med. 1994, 331, 1188-1193. - 35. Owens, D. R„ Coates, P. A., Luzio, S. D. és mtsai: Pharmakokinetics of 1251-labeled insulin glargyn (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care, 2000, 23, 813-819. 36. Piemonti, L„ Calori, G„ Mercoli, A. és mtsai: Fasting plasma leptin, tumor-necrosis factor-alpha-receptor 2, and mo­nocyte chemoattracting protein 1 concentration in a population of glucose tolerant, and gucose-intolerant women. Impact on car­diovascular mortality. Diabetes Care, 2003, 26, 2883-2881. - 37. Pickup, J. C.: Inflammation and activated Innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care, 2004,27, 813-823. - 38. Pickup, J. C., Keen, H.: Continous subcutaneous insulin infu­sion of 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care, 2002, 25, 593- 598. - 39. Princz S.: Az infectológia feladatai az aterogenezis kuta­tásban. Metabolizmus, 2003, 1, 9-11. - 40. Raheja, B. S.: Indian diet-diabetes and it's complications. IDF Bulk, 1988, 33, 14-17. - 41. Kömer, A., Madácsy, L„ Tulassay, T: Increasing prevalence of type 2 diabetes mellitus in children and adolescents in Hungary. Diab. Res. and Clin. Practice, Abstract Book, 2000, 50, (Suppl. 1), 206. - 42. Reaven, G. R.: The role of insulin resistance in human disease. Diabetes, 1988, 37, 1595-1607. - 43. Robertson, R. R, Da­vis, C„ Larsen, J. és mtsai: Pancreas and islet transplantation for pa­tients with diabetes mellitus. (Technical Review) Diabetes Care, 2000, 23, 112-116. - 44. Rosenson, R. S„ Tanguey, C. C„ Casey, L. C.: Inhibition of proinflammatory cytokine production by pravasta­tin (letter) Lancet, 1999, 353, 983-984. - 45. Ryan, E. A., Imes, S., Wallace, C.: Short-term intensive insulin therapy in newly diagno­sed type 2 diabetes. Diabetes Care, 2004, 27, 1028-1032. - 46. Schulze, M. B„ Rimm, E. B., Li, T. és mtsai: C-reactive protein and in­cident cardiovascular events among men with diabetes. Diabetes Care, 2004, 27, 889-894. - 47. Spin, J. M„ Vagelos, R. H.: Korai sta­tin kezelés akut coronaria szindrómában. Current Atherosclerosis Reports (magyar nyelvű kiadás), 2003, 3, 645-654. - 48. Sigurdat­­totir, V, Fagerberg, B., Hulthe, J.: Preclinical atherosclerosis and inf­lammation in 61-year-old men with newly diagnosed diabetes and established diabetes. Diabetes Care, 2004, 27, 880-884. - 49. Tamás Gy., Jermendy Gy., Herényi Zs. és mtsai: A tiazolidin-dionok („glitazonok") helye a diabetes mellitus kezelésében. Diabetok Hung., 2004, XII, 39-49. - 50. Tominaga, M„ Eguchi, H„ Manaka, H. és mtsai: Impaired glucose tolerance is a risk factor for cardiovas­cular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 1999, 22, 920-924. - 51. U. K. Pro­spective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet, 1998, 352, 837-85 3. - 52. U. K. Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascu­­lar complications in type 2 diabetes (UKPDS 38) Br. Med. J., 1998, 317, 703-713. - 53. Yki-Jaervinen, H.: Combination therapy with insulin in type 2 diabetes. Diabetes Care, 2001, 24, 758-767. - 54. Yiging, S„ Manson, J. E., Buring, J. E. és mtsai: Dietary magne­sium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care, 2004, 27, 59-63. - 55. Yusuf, S., Gerstein, A„ Hoogwerf, B. és mtsai: Ramipril and the development of diabetes. JAMA, 2001, 286, 1882-1885. - 56. Young, A., Dena­­ro, M.: Roles of amylin in diabetes and in regulation of nutrient lo­ad (editorial). Nutrition, 1998, 14, 524-527. - 57. Vilsbol, T, Holst, J. J.: Incretins, insulin secretion and type 2 diabetes mellitus Dia­betologia, 2004, 47, 357-366. (Halmos Tamás dr., Budapest, Kikelet u. 43/b. 1125 e-mail: fishwash@axelero.hu) 2370 ORVOSI VJ IX V VJ J 1 HETILAP 2004 • 145. évfolyam, 47. szám

Next